Table 2.
Direct-acting antiviral (DAA) therapy, HCV RNA viral load, adverse events, and treatment response.
| Patient ID | DAA Therapy * | HCV RNA (IU/mL) | Adverse Events | SVR 12 | |||||
|---|---|---|---|---|---|---|---|---|---|
| – | – | Baseline | 4 Weeks | 12 Weeks | 24 Weeks | 36 Weeks | 48 Weeks | – | – |
| HCV04 | TVR | 7,410,000 | TND | TND | TND | TND | TND | None | Yes |
| HCV06 | TVR | 1,580,000 | <15 | TND | TND | TND | TND | None | Yes |
| HCV08 | TVR | 2,090,000 | TND | TND | TND | TND | TND | None | Yes |
| HCV09 | TVR | 7,930,000 | <15 | TND | TND | TND | TND | Anemia | Yes |
| HCV17 | TVR | 2,170,000 | <15 | TND | TND | TND | TND | Anemia | Yes |
| HCV19 | TVR | 4,290,000 | <15 | TND | TND | TND | TND | None | Yes |
| HCV20 | TVR | 1,520,000 | TND | TND | TND | TND | TND | Anemia and Neutropenia | Yes |
| – | – | Baseline | 4 Weeks | 8 Weeks | 12 Weeks | 24 Weeks | 36 Weeks | – | – |
| HCV21 | BOC | 1,030,000 | 11,900 | <15 | TND | TND | TND | Anemia | Yes |
SVR = Sustained Virological Response; TND = Target Not Detected; * Patients HCV04, HCV06, HCV09, HCV17, HCV19 and HCV20 were treated with pegylated interferon-α plus ribavirin (PegIFN-α/RBV) + telaprevir (TVR) for 12 weeks, afterward with PegIFN-α/RBV for 36 weeks; Patient HCV08 was treated with PegIFN-α/RBV + TVR for 12 weeks, afterward with PegIFN-α/RBV for 12 weeks; Patient HCV21 was treated with PegIFN-α/RBV for 4 weeks, afterward with PegIFN-α/RBV + boceprevir (BOC) for 44 weeks.